PAISLEY LB004 @EricFMorand on deucravacitinib phase 2 for SLE ⭐️Meets primary endpt: SRI(4) ⭐️Secondary endpts: BICLA, LLD, CLASI, jt count, biomarkers improved ⭐️Safety data wo VTE, CVD events Earlier at #EULAR2022, BRAVE trial phase 3 baricitinib: No benefit in SLE @RheumNow https://t.co/3YpPSJcenF

PAISLEY study Phase 2 RCT Deucravacitinib in SLE meets primary endpoint wk 32 Results for dose 3mg BID: *SRI(4) response 58.2% vs. PBO 34% *LLDAS 36% *CLASI 70% *⬇️ SJC No new safety signal Now waiting for Phase 3 👀 @RheumNow LB0004 #EULAR2022 #Lupus https://t.co/2KYSvfq4h7

New in AS. Upadacitinib 15mg od was significantly more effective than placebo over 14 weeks in AS bDMARD-IR (ASAS40 45% vs 18% and the onset of effect seen by week 4), no new safety risks identified in the SELECT-AXIS 2 study by Van de Heijde et al #EULAR2022 @RheumNow POS0306 https://t.co/LCQBf38GWe

SELECT-AXIS 1 trial of upadacitinib in active #AS with an inadequate resp to prior biologic - pivotal phase 2/3 RCT of 420 AS pts (Dz dur 7.7 yrs; 83% B27+) showed better ASAS40 at wk 14 w/ UPA vs PBO (45% vs 18%; P<0.0001) #EULAR2022 POS0306 https://t.co/6ZBEvjRjqc https://t.co/GL0vlB34mE

• https://bit.ly/3zdWc6A

Please see my short video on Promising Safety Outlook for Rituximab and Baricitinib in Vaccinated Patients #EULAR2022 @RheumNow https://t.co/bqzdWIzoOg

• Promising Safety Outlook for Rituximab and Baricitinib in Vaccinated Patients -…

Frisell et al. Safety b/tsDMARDs from 10 years ARTIS. There is a mass of interesting data here, look at that figure! Higher rates of discontinuation due to AEs for tofa, bari, sari, rituximab. May be explained by chanelling and residual confounding @RheumNow #EULAR2022 POS0637 https://t.co/KrspU6c9Cs

What drives residual pain improvement in #JAKi treated pts? Dunno but #Baricitinib and #Sarilimab showed better pain decrease vs placebo and #Adalimumab. #OP0052 showed both #Tofacitinib & Adalimumab reduced pain more than placebo in PsA & RA if in remission @RheumNow @eular_org